Canntab Therapeutics Limited, the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein, currently serving as Canntab’s CFO, as interim CEO of Canntab, effective July 31, 2022.
Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.
About Canntab Therapeutics
Canntab is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These include once a day and extended-release formulations, both providing an accurate dose and improved shelf stability.